Haleon (HLN) EBIT Margin (2021 - 2023)

Haleon (HLN) recorded quarterly EBIT Margin of 20.87% in Q4 2023, up 11.75% on a QoQ basis from 18.68% in Q2 2023, and down 79.0% year-over-year from 99.39% in Q4 2022.

Haleon (HLN) EBIT Margin (2021 - 2023) Analysis & Trends

Haleon has disclosed EBIT Margin across 3 years of filings, most recently posting 20.87% for Q4 2023.

  • Quarterly EBIT Margin fell 79.0% year-over-year to 20.87% in Q4 2023, while the trailing twelve-month figure through Dec 2023 was 20.53% (changed N/A YoY) and the FY2025 annual result came in at 21.87%, up 223.0% from the prior year.
  • EBIT Margin climbed to 20.87% in Q4 2023, from 18.68% in the prior quarter.
  • Over five years, EBIT Margin peaked at 21.66% in Q4 2022 and troughed at 18.68% in Q2 2023.
  • A 3-year average of 20.51% and a median of 20.87% in 2023 frame the typical range for EBIT Margin.
  • Annual changes were most pronounced in 2022 — EBIT Margin jumped 130 bps — and 2023, when it slumped 79 bps.
  • Tracing HLN's EBIT Margin over 3 years: stood at 20.36% in 2021, then climbed by 6 bps to 21.66% in 2022, then retreated by 4 bps to 20.87% in 2023.
  • Business Quant data shows HLN's EBIT Margin at 20.87% in Q4 2023, 18.68% in Q2 2023, and 21.0% in Q2 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Margin (Qtr)
1 Teva Pharmaceutical Industries 39.72 Bn 35.98 Bn 1.97 Bn 16.37%
2 Zoetis 34.61 Bn 32.67 Bn 1.62 Bn 36.83%
3 United Therapeutics 24.07 Bn 21.91 Bn 648.10 Mn 41.69%
4 Aurora Cannabis 16.98 Bn 16.91 Bn 33.43 Mn 20.77%
5 Neurocrine Biosciences 16.64 Bn 15.32 Bn 800.70 Mn 23.74%
6 Elanco Animal Health 12.19 Bn 11.76 Bn 785.00 Mn 22.39%
7 Alkermes 7.37 Bn 6.86 Bn -116.06 Mn -122.23%
8 Hims & Hers Health 6.62 Bn 5.87 Bn 396.79 Mn -12.88%
9 Lantheus Holdings 6.47 Bn 5.97 Bn 230.92 Mn 21.55%
10 Haleon 1.09 Bn -773.69 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2023 20.87%
Jun 30, 2023 18.68%
May 3, 2023 21.00%
Dec 31, 2022 21.66%
Dec 31, 2021 20.36%